Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Katrine D. Galsgaard"'
Autor:
Katrine D. Galsgaard, Emilie Elmelund, Christian D. Johansen, Anna B. Bomholt, Hüsün S. Kizilkaya, Frederik Ceutz, Jenna E. Hunt, Hannelouise Kissow, Marie Winther-Sørensen, Charlotte M. Sørensen, Thomas Kruse, Jesper F. Lau, Mette M. Rosenkilde, Cathrine Ørskov, Christina Christoffersen, Jens J. Holst, Nicolai J. Wewer Albrechtsen
Publikováno v:
Molecular Metabolism, Vol 66, Iss , Pp 101639- (2022)
Objective: Treatment with glucagon receptor antagonists (GRAs) reduces blood glucose but causes dyslipidemia and accumulation of fat in the liver. We investigated the acute and chronic effects of glucagon on lipid metabolism in mice. Methods: Chronic
Externí odkaz:
https://doaj.org/article/a7ae536eaac7430393a76a080bee5d30
Autor:
Emilie Elmelund, Katrine D. Galsgaard, Christian D. Johansen, Samuel A.J. Trammell, Anna B. Bomholt, Marie Winther-Sørensen, Jenna E. Hunt, Charlotte M. Sørensen, Thomas Kruse, Jesper F. Lau, Trisha J. Grevengoed, Jens J. Holst, Nicolai J. Wewer Albrechtsen
Publikováno v:
iScience, Vol 25, Iss 11, Pp 105296- (2022)
Summary: The pancreatic hormone, glucagon, is known to regulate hepatic glucose production, but recent studies suggest that its regulation of hepatic amino metabolism is equally important. Here, we show that chronic glucagon receptor activation with
Externí odkaz:
https://doaj.org/article/300e9213de6c4cefb0c83693badfc6e2
Autor:
Sara L. Jepsen, Nicolai J. Wewer Albrechtsen, Johanne A. Windeløv, Katrine D. Galsgaard, Jenna E. Hunt, Thomas B. Farb, Hannelouise Kissow, Jens Pedersen, Carolyn F. Deacon, Rainer E. Martin, Jens J. Holst
Publikováno v:
JCI Insight, Vol 6, Iss 4 (2021)
Somatostatin (SS) inhibits glucagon-like peptide-1 (GLP-1) secretion in a paracrine manner. We hypothesized that blocking somatostatin subtype receptor 2 (SSTR2) and 5 (SSTR5) would improve glycemia by enhancing GLP-1 secretion. In the perfused mouse
Externí odkaz:
https://doaj.org/article/49e4ec3cf7a24f8eaa5ee947eda8a17d
Autor:
Marie Winther-Sørensen, Katrine D. Galsgaard, Alberto Santos, Samuel A.J. Trammell, Karolina Sulek, Rune E. Kuhre, Jens Pedersen, Daniel B. Andersen, Anna S. Hassing, Morten Dall, Jonas T. Treebak, Matthew P. Gillum, Signe S. Torekov, Johanne A. Windeløv, Jenna E. Hunt, Sasha A.S. Kjeldsen, Sara L. Jepsen, Catherine G. Vasilopoulou, Filip K. Knop, Cathrine Ørskov, Mikkel P. Werge, Hanne Cathrine Bisgaard, Peter Lykke Eriksen, Hendrik Vilstrup, Lise Lotte Gluud, Jens J. Holst, Nicolai J. Wewer Albrechtsen
Publikováno v:
Molecular Metabolism, Vol 42, Iss , Pp 101080- (2020)
Objective: Glucagon is well known to regulate blood glucose but may be equally important for amino acid metabolism. Plasma levels of amino acids are regulated by glucagon-dependent mechanism(s), while amino acids stimulate glucagon secretion from alp
Externí odkaz:
https://doaj.org/article/b7bfa9036b094c1691ac479159a7df74
Autor:
Nicolai J. Wewer Albrechtsen, Rune E. Kuhre, Daniel Hornburg, Christian Z. Jensen, Mads Hornum, Carsten Dirksen, Maria Svane, Lærke S. Gasbjerg, Nils B. Jørgensen, Maria N. Gabe, Emilie Balk-Møller, Reidar Albrechtsen, Marie Winther-Sørensen, Katrine D. Galsgaard, Felix Meissner, Tina Jorsal, Asger Lund, Tina Vilsbøll, Rasmus Eliasen, Kirstine N. Bojsen-Møller, Thomas Idorn, Carolyn F. Deacon, Filip K. Knop, Mette M. Rosenkilde, Bolette Hartmann, Bo Feldt-Rasmussen, Matthias Mann, Sten Madsbad, Jens J. Holst
Publikováno v:
Cell Reports, Vol 21, Iss 6, Pp 1452-1460 (2017)
Summary: Glucagon is secreted from pancreatic α cells, and hypersecretion (hyperglucagonemia) contributes to diabetic hyperglycemia. Molecular heterogeneity in hyperglucagonemia is poorly investigated. By screening human plasma using high-resolution
Externí odkaz:
https://doaj.org/article/b5aa1694774f4b23bb8fed0e16aceb6a
Autor:
Katrine D. Galsgaard, Jens Pedersen, Filip K. Knop, Jens J. Holst, Nicolai J. Wewer Albrechtsen
Publikováno v:
Frontiers in Physiology, Vol 10 (2019)
Glucagon is secreted from the pancreatic alpha cells upon hypoglycemia and stimulates hepatic glucose production. Type 2 diabetes is associated with dysregulated glucagon secretion, and increased glucagon concentrations contribute to the diabetic hyp
Externí odkaz:
https://doaj.org/article/4992c6d3e69a442c8d94ac0720bd5f29
Autor:
EMILIE E. CHRISTENSEN, KATRINE D. GALSGAARD, CHRISTIAN D. JOHANSEN, SAMUEL TRAMMELL, ANNA B. BOMHOLT, JENNA HUNT, THOMAS KRUSE, JESPER F. LAU, TRISHA GREVENGOED, JENS J. HOLST, NICOLAI J. WEWER ALBRECHTSEN
Publikováno v:
Diabetes. 71
Amino acids control alpha cell secretion and growth, while glucagon stimulates hepatic amino acid uptake and ureagenesis, forming the liver-alpha cell axis. Patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes have increased lev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03db0b4147ca740e0e15837aac213940
https://doi.org/10.2337/db22-214-lb
https://doi.org/10.2337/db22-214-lb
Autor:
KATRINE D. GALSGAARD, EMILIE E. CHRISTENSEN, ANNA B. BOMHOLT, JENNA HUNT, THOMAS KRUSE, JESPER F. LAU, CHRISTINA CHRISTOFFERSEN, JENS J. HOLST, NICOLAI J. WEWER ALBRECHTSEN
Publikováno v:
Diabetes. 71
Glucagon receptor antagonists (GRAs) reduce blood glucose in subjects with type 2 diabetes (T2D) but may cause dyslipidemia. Increased plasma triglyceride (TG) levels in patients with T2D are thought to be caused partly by insulin resistance but it i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5643c0a719b87f2de9f6508785ee3f1c
https://doi.org/10.2337/db22-1332-p
https://doi.org/10.2337/db22-1332-p
Autor:
Michael M. Richter, Katrine D. Galsgaard, Emilie Elmelund, Filip K. Knop, Malte P. Suppli, Jens J. Holst, Marie Winther-Sørensen, Sasha A.S. Kjeldsen, Nicolai J. Wewer Albrechtsen
Publikováno v:
Diabetes. 71(9)
Glucagon and insulin are the main regulators of blood glucose. While the actions of insulin are extensively mapped, less is known about glucagon. Besides glucagon’s role in glucose homeostasis, there are additional links between the pancreatic α-c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f983f0f7dda76cfb37f994eebd41b4f
https://pubmed.ncbi.nlm.nih.gov/35657688
https://pubmed.ncbi.nlm.nih.gov/35657688
Autor:
Anna Billeschou Bomholt, Christian Dall Johansen, Sasha A. S. Kjeldsen, Katrine D. Galsgaard, Jens Bager Christensen, Marie Winther-Sørensen, Reza Serizawa, Mads Hornum, Esteban Porrini, Jens Pedersen, Cathrine Ørskov, Lise L. Gluud, Charlotte Mehlin Sørensen, Jens J. Holst, Reidar Albrechtsen, Nicolai J. Wewer Albrechtsen
Publikováno v:
Bomholt, A B, Johansen, C D, Christensen, J B, Kjeldsen, S A S, Galsgaard, K D, Winther-Sørensen, M, Serizawa, R, Hornum, M, Porrini, E, Pedersen, J, Ørskov, C, Gluud, L L, Sørensen, C M, Holst, J J, Albrechtsen, R & Wewer Albrechtsen, N J 2022, ' Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression ', Communications Biology, vol. 5, no. 1, 1278 . https://doi.org/10.1038/s42003-022-04242-7
Glucagon is a key regulator of numerous metabolic functions including glucose, protein and lipid metabolism, and glucagon-based therapies are explored for diabetes, fatty liver disease and obesity. Insight into tissue and cell specific expression of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deed2a2ff720b0aae1000d5305e0e5e5
https://curis.ku.dk/ws/files/327932782/Evaluation_of_commercially.pdf
https://curis.ku.dk/ws/files/327932782/Evaluation_of_commercially.pdf
